Construction and immunogenicity of a recombinant fowlpox virus containing the capsid and 3C protease coding regions of foot-and-mouth disease virus.
Foot-and-mouth disease virus (FMDV) is an important pathogen with worldwide economic consequences. Consequently, an important goal is the development of a vaccine that can provide rapid protection while overcoming the potential risk associated with the production of conventional inactivated vaccines. An important secondary feature of the vaccine would be the ability to distinguish vaccinated from infected animals. A recombinant fowlpox virus (vUTAL3CP1) containing FMDV capsid polypeptide and 3C coding regions of O/NY00 was constructed and evaluated for its ability to induce humoral and cellular responses in mice and guinea pigs. In addition, the ability to protect guinea pigs against homologous virus challenge was examined. Mice and guinea pigs were given booster vaccinations twice and once, respectively, and guinea pigs were challenged 20 days after the booster vaccination. Control groups included animals inoculated with commercial vaccine, fowlpox virus or phosphate-buffered saline (PBS). All animals vaccinated with vUTAL3CP1 developed specific anti-FMDV antibody and neutralizing antibody, as well as T lymphocyte proliferation response and CTL cytotoxic activity. Three of four guinea pigs vaccinated with vUTAL3CP1 were completely protected from viral challenge. The results demonstrated the potential of a fowlpox virus-based recombinant FMD vaccine.
Zheng
Min
M
Genetic Engineering Laboratory of PLA, Academy of Military Medical Sciences of PLA, Changchun 130062, PR China.
Jin
Ningyi
N
Zhang
Hongyong
H
Jin
Minglan
M
Lu
Huijun
H
Ma
Minxiao
M
Li
Chang
C
Yin
Gefen
G
Wang
Ruilin
R
Liu
Qi
Q
D000086042:3C Viral Proteases; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D036022:Capsid Proteins / Q000235:genetics / Q000276:immunology*; D003546:Cysteine Endopeptidases / Q000235:genetics / Q000276:immunology*; D003601:Cytotoxicity Tests, Immunologic; D004195:Disease Models, Animal; D005536:Foot-and-Mouth Disease / Q000276:immunology / Q000517:prevention & control; D029544:Foot-and-Mouth Disease Virus / Q000201:enzymology / Q000235:genetics / Q000276:immunology*; D005587:Fowlpox virus / Q000235:genetics* / Q000276:immunology; D006168:Guinea Pigs; D007117:Immunization, Secondary; D051379:Mice; D009500:Neutralization Tests; D013601:T-Lymphocytes / Q000276:immunology; D014614:Vaccines, Synthetic / Q000235:genetics / Q000276:immunology; D014764:Viral Proteins / Q000235:genetics / Q000276:immunology*; D014765:Viral Vaccines / Q000235:genetics / Q000276:immunology*
D000914:Antibodies, Viral; D036022:Capsid Proteins; D014614:Vaccines, Synthetic; D014764:Viral Proteins; D014765:Viral Vaccines; D003546:Cysteine Endopeptidases; D000086042:3C Viral Proteases